Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. Issue 8 (14th August 2013)

• Record Type: Journal Article
• Authors: Kittelson, J. M.; Spyropoulos, A. C.; Halperin, J. L.; Kessler, C. M.; Schulman, S.; Steg, G.; Turpie, A. G. G.; Cutler, N. R.; Hiatt, W. R.; Goldenberg, N. A.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 11:Issue 8(2013)
• Page Start: 1443
• Page End: 1448
• Publication Date: 2013-08-14
• Subjects: Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.12324
• Languages: English
• ISSNs: 1538-7933

Abstract

<abstract abstract-type="main" id="jth12324-abs-0001"> <title>Summary</title> <p>Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate safety endpoint. Findings often occur in opposition (i.e. decreased thromboembolism accompanied by increased bleeding, or vice‐versa), leading to variable interpretation of the results, which may ultimately be judged as equivocal. In this paper, we offer an alternative to traditional designs based on the concept of a bivariate primary endpoint that accounts for simultaneous effects on antithrombotic efficacy and harm due to bleeding. We suggest a bivariate endpoint as a general approach to the assessment of 'net clinical benefit' in recently published trials and to the design of future trials. Lastly, we illustrate the bivariate endpoint design using two examples: a recently published superiority trial of rivaroxaban (RECORD1) and an ongoing non‐inferiority trial of the duration of anticoagulant therapy in children with venous thrombosis (Kids‐DOTT).</p> </abstract>